Close Menu
    Facebook X (Twitter) Instagram
    Facebook Instagram Threads
    Global BiodefenseGlobal Biodefense
    Subscribe
    • Featured News
    • Funding
    • Directory
    • Jobs
    • Events
    Global BiodefenseGlobal Biodefense
    Health Security

    iBio Plague Vaccine Patent Emerges From Opposition Period

    By Global Biodefense StaffMarch 30, 2015
    Share
    Facebook LinkedIn Reddit Email

    iBio, Inc. today announced it received notice from the European Patent Office that the opposition period expired for a bio-defense product patent granted to iBio, and no opposition was filed.

    The patent, entitled “Yersinia Pestis Antigens, Vaccine Compositions and Related Methods” (European patent EP 2178558), includes claims covering plague antigens fused to a thermostable protein such as the Company’s iBioModulator thermostable immunomodulator, as well as vaccine compositions and a method for producing the antigen.

    “This is an important extension of our commercial platform,” said Robert Erwin, iBio’s president. “We expect our success with vaccine and therapeutic product candidates for use against serious infectious disease agents with weapon potential, such as plague bacillus, to be of interest to governments and companies engaged in supplying disease countermeasures.”

    iBio technology has been successfully applied to the creation of vaccine candidates for plague and for a plague-anthrax combination vaccine with development and testing funded by the U.S. government.

    The U.S. Centers for Disease Control and Prevention classify plague as a Category A disease, which means “it poses a risk to national security because it can be easily disseminated or transmitted from person to person, results in high mortality rates and has the potential for a major public health impact, might cause public panic and social disruption, and requires special action for public health preparedness.”

    There is no plague vaccine currently approved for use in the U.S. Although killed whole-cell plague vaccines have been reported to protect against bubonic plague in animal models, such vaccines were not effective against pneumonic plague. By contrast, data previously published in the peer-reviewed scientific journal, Vaccine, demonstrated that a recombinant plague vaccine incorporating the iBioModulator protein, and produced via the iBioLaunch gene expression platform in green plants, provided full protection of non-human primates against aerosolized Y. pestis (pneumonic plague).

    Additional infectious disease and bio-defense applications of iBio technology include an anthrax vaccine currently in a Phase 1 human clinical trial and therapeutic antibodies targeting pathogens such as influenza virus, respiratory syncytial virus, and Ebola virus.

    Source: iBio press release, adapted.

    Animal Models Vaccine News Y. pestis
    Share. Facebook LinkedIn Reddit Email
    Previous ArticleEbola Vaccine Trial in Liberia Advancing to Phase 3
    Next Article RFI – Diagnostic Devices for Biological, Chemical and Nuclear Threats

    Related Stories

    First Light Diagnostics Receives FDA Clearance for Rapid Anthrax Test

    December 5, 2023

    Chlorine Exposure Biomarkers in a Large Animal Model

    December 5, 2023

    Human BCG Challenge Model for Assessment of Tuberculosis Immunity

    December 2, 2023

    Needle-Free Vaccine Patch Against Zika Virus

    December 2, 2023
    News Scan

    Biodefense Headlines – 30 November 2023

    News Scan November 30, 2023

    News highlights on health security threats and countermeasures curated by Global Biodefense This week’s selections include the largest ever outbreak of mpox in the DRC; launch of National Wastewater Surveillance Program dashboard; low uptake of COVID-19 boosters and flu vaccines;…

    Upcoming Events

    Mar 12
    Hybrid Hybrid Event
    March 12, 2024 - March 17, 2024

    2024 Fungal Genetics Conference

    Mar 21
    March 21, 2024 - March 23, 2024

    ASPPH 2024 Annual Meeting

    View Calendar

    Subscribe to Global Biodefense

    Get the latest news on pathogens and preparedness

    News on pathogens and preparedness for public health emergencies

    © 2023 Stemar Media Group LLC
    • About
    • Contact
    • Privacy
    • Subscribe

    Type above and press Enter to search. Press Esc to cancel.